AVDL [NASD]
Avadel Pharmaceuticals plc
Index- P/E- EPS (ttm)-1.54 Insider Own0.80% Shs Outstand58.82M Perf Week56.41%
Market Cap205.22M Forward P/E- EPS next Y-1.05 Insider Trans131.74% Shs Float35.64M Perf Month48.18%
Income-90.30M PEG- EPS next Q-0.30 Inst Own61.40% Short Float16.71% Perf Quarter-45.21%
Sales- P/S- EPS this Y-21.20% Inst Trans2.15% Short Ratio1.44 Perf Half Y-55.85%
Book/sh0.94 P/B3.89 EPS next Y102.50% ROA-35.60% Target Price9.30 Perf Year-48.31%
Cash/sh2.20 P/C1.66 EPS next 5Y15.00% ROE-102.80% 52W Range1.05 - 11.59 Perf YTD-54.70%
Dividend- P/FCF- EPS past 5Y-5.70% ROI- 52W High-68.42% Beta1.03
Dividend %- Quick Ratio3.70 Sales past 5Y- Gross Margin- 52W Low248.57% ATR0.41
Employees66 Current Ratio3.70 Sales Q/Q- Oper. Margin- RSI (14)64.64 Volatility17.16% 10.09%
OptionableYes Debt/Eq2.59 EPS Q/Q-95.30% Profit Margin- Rel Volume0.37 Prev Close3.60
ShortableYes LT Debt/Eq2.11 EarningsMay 09 BMO Payout- Avg Volume4.14M Price3.66
Recom1.50 SMA2049.60% SMA509.88% SMA200-46.25% Volume1,542,572 Change1.67%
May-26-22Downgrade Stifel Buy → Hold $9 → $2
Sep-23-21Initiated Needham Buy $17
Jul-31-20Initiated Oppenheimer Outperform $19
Jul-21-20Initiated SVB Leerink Outperform $17
Jun-30-20Initiated H.C. Wainwright Buy $15
Apr-03-20Initiated Jefferies Buy $14
Mar-12-20Initiated Stifel Buy $14
Feb-26-20Initiated Piper Sandler Overweight $14
Jan-30-20Initiated Craig Hallum Buy $15
Jun-14-19Upgrade Ladenburg Thalmann Neutral → Buy $6
Feb-08-19Downgrade Ladenburg Thalmann Buy → Neutral
Jun-30-22 08:09AM  
Jun-29-22 04:05PM  
Jun-03-22 08:00AM  
Jun-02-22 08:00AM  
06:07AM  
May-26-22 09:09AM  
May-19-22 08:00AM  
May-18-22 08:00AM  
May-09-22 10:05AM  
07:00AM  
May-02-22 08:00AM  
Apr-28-22 08:00AM  
Apr-26-22 11:38AM  
07:30AM  
Apr-25-22 08:00AM  
Apr-06-22 08:00AM  
Mar-22-22 08:00AM  
Mar-17-22 07:00AM  
Mar-14-22 04:30PM  
08:00AM  
Mar-11-22 07:00AM  
Mar-10-22 04:30PM  
Mar-01-22 07:00AM  
Feb-22-22 11:40AM  
Feb-14-22 07:00AM  
Feb-10-22 07:00AM  
Dec-08-21 08:30AM  
Nov-24-21 04:19AM  
Nov-22-21 08:00AM  
Nov-09-21 08:00AM  
Nov-08-21 03:30PM  
08:00AM  
Nov-04-21 03:07AM  
Nov-01-21 04:37PM  
08:00AM  
Oct-29-21 05:38PM  
Oct-26-21 01:32AM  
Oct-20-21 07:17PM  
Oct-19-21 08:00AM  
Oct-18-21 07:02PM  
02:12PM  
08:18AM  
07:02AM  
Oct-15-21 05:00PM  
Oct-03-21 09:00AM  
Sep-29-21 08:32AM  
Sep-20-21 08:00AM  
Sep-03-21 09:32AM  
Sep-02-21 08:00AM  
Aug-26-21 06:14AM  
Aug-16-21 08:00AM  
Aug-09-21 02:30PM  
08:00AM  
Aug-02-21 08:00AM  
Jul-07-21 08:00AM  
Jun-27-21 03:36AM  
Jun-09-21 09:00AM  
Jun-03-21 08:00AM  
Jun-02-21 08:00AM  
May-25-21 08:00AM  
May-13-21 02:00AM  
May-10-21 06:00PM  
08:00AM  
06:45AM  
Apr-29-21 08:00AM  
Apr-19-21 07:05AM  
Apr-17-21 08:00AM  
Apr-08-21 08:00AM  
Mar-29-21 01:22AM  
Mar-18-21 08:00AM  
Mar-09-21 03:00PM  
07:00AM  
05:30AM  
Mar-04-21 08:00AM  
Mar-02-21 08:00AM  
Mar-01-21 12:10PM  
08:00AM  
Feb-25-21 08:00AM  
Feb-23-21 06:20PM  
Feb-17-21 08:00AM  
Feb-10-21 08:00AM  
Dec-28-20 11:47PM  
Dec-16-20 02:21PM  
08:00AM  
Dec-15-20 08:00AM  
Dec-07-20 08:00AM  
Nov-23-20 08:00AM  
Nov-11-20 08:00AM  
Nov-09-20 06:30PM  
07:00AM  
06:30AM  
Oct-26-20 08:00AM  
Oct-07-20 10:38AM  
Sep-30-20 06:58AM  
Sep-17-20 08:00AM  
Sep-14-20 08:00AM  
Sep-11-20 04:35PM  
Aug-18-20 08:42AM  
Aug-11-20 01:30AM  
Aug-10-20 08:34AM  
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Glass Geoffrey MichaelDirectorJun 01Buy2.1445,00096,30045,000Jun 02 04:02 PM
Ende Eric JDirectorJun 01Buy2.2720,00045,496134,900Jun 01 06:59 PM
Ende Eric JDirectorMay 31Buy2.1615,00032,394114,900Jun 01 06:59 PM
Thornton Peter J.DirectorMay 27Buy1.6950,00084,50083,055May 31 07:12 AM
Divis Gregory JChief Executive OfficerMay 27Buy2.0550,000102,500149,100May 31 07:13 AM
Ende Eric JDirectorMay 27Buy2.4515,00036,74799,900May 31 07:14 AM
MCHUGH THOMAS SChief Financial OfficerMay 27Buy2.1450,000106,89571,500May 31 07:15 AM
Palczuk LindaDirectorMay 27Buy1.6010,00016,00047,900May 31 07:17 AM